Sugi Predict

Sugi Predict / Compounds / SCHEMBL390880

SCHEMBL390880

SCHEMBL390880

NC(CS(N)(=O)=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABBR2 O75899 4/20 0.49
▸ GABBR1 Q9UBS5 4/20 0.49
▸ CA1 P00915 3/20 0.45
▸ CA2 P00918 3/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA3 P07451 1/20 0.45
▸ CA4 P22748 1/20 0.45
▸ CA6 P23280 1/20 0.45
▸ CA5A P35218 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA13 Q8N1Q1 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ CA5B Q9Y2D0 1/20 0.45
▸ ADRB2 P07550 1/20 0.45
▸ PTGES2 Q9H7Z7 2/20 0.43
▸ SCN4A P35499 2/20 0.41
▸ CYP2C9 P11712 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6032624 0.84 GABBR2 (0.64) GABBR2GABBR1CA1CA2ADRB2
SCHEMBL391585 0.82 CA1 (0.41) GABBR2GABBR1CA1CA2CA9
SCHEMBL8526440 0.78 GBA1 (0.52) CA1CA2CA9CA5APTGES2
SCHEMBL28956466 0.78 HSD11B1 (0.47) GABBR2GABBR1PTGES2SCN4AMEN1
SCHEMBL27904943 0.73 ADRB2 (0.52) GABBR2GABBR1ADRB2SCN4ACYP2C9
SCHEMBL27904852 0.73 ADRB2 (0.52) GABBR2GABBR1ADRB2SCN4ACYP2C9
SCHEMBL1953110 0.73 ADRB2 (0.52) GABBR2GABBR1ADRB2SCN4ACYP2C9
SCHEMBL14142191 0.73 ADRB2 (0.52) GABBR2GABBR1ADRB2SCN4ACYP2C9
SCHEMBL390242 0.72 GBA1 (0.46) GABBR2GABBR1CA1CA2ADRB2
Hydrochloric Acid SCHEMBL25367507 0.71 ADRB2 (0.50) GABBR2GABBR1ADRB2SCN4ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
CN-101861321-A Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2010-10-13 — — CN disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 GABBR2 2327/4885GABBR1 3042/4885CA1 3988/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 GABBR2 2327/4885GABBR1 3042/4885CA1 3988/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 GABBR2 2327/4885GABBR1 3042/4885CA1 3988/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 GABBR2 2682/4885GABBR1 3278/4885CA1 4458/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 GABBR2 2327/4885GABBR1 3042/4885CA1 3988/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 GABBR2 2682/4885GABBR1 3278/4885CA1 4458/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 GABBR2 2327/4885GABBR1 3042/4885CA1 3988/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 GABBR2 2327/4885GABBR1 3042/4885CA1 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.